- adequate taxation, which can be best effected by the combination of a direct duty with the auction of the privilege of vend (Chapter XIV, paragraph 587)
- prohibiting cultivation, except under licence, and centralising cultivation (Chapter XVI, paragraphs 636 and 677)
- limiting the number of shops for the retail sale of hemp drugs (Chapter XVI, paragraph 637)
- limiting the extent of legal possession (Chapter XVI, paragraphs 689 and 690)
- clear and explicit decriminalisation of the possession of one or more currently controlled substances for personal use;
- the creation of a regulated, non-medical market in one or more controlled substances.
In February 2016, a spokesperson for Australia's Federal Health Minister outlined the Government’s current position regarding the use of medical Cannabis in Australia as "supportive of use for medicinal purposes where it is evidence-based and backed by good science to ensure favourable patient outcomes". However, the Government is concerned about people accessing illicit Cannabis supplies, exposing themselves to risk without medical supervision and increasing adverse results. The Minister announced the Government’s intention to enable cultivation on 17 October 2015 and legislation to enable this is intended to be introduced in the week commencing 8 February 2016. The Office of Drug Control within the Department of Health will be responsible for overseeing the cultivation scheme. Once the Secretary is satisfied there is a lawful use, cultivators will be granted a licence, subject to conditions to ensure Cannabis is not diverted for illicit uses (the Office will monitor compliance).
"There have always been legal pathways to access Cannabis products for medicinal purposes under the Therapeutic Goods Act 1989 ... however, these have been poorly used. In part, this is because of difficulty in getting a supply of products to import", the government spokesperson said. The Government believes by cultivating and manufacturing locally, appropriately manufactured products will be assured. When medical practitioners become aware of the availability of product and evidence is available of its safety and efficacy, they can consider it within their clinical practice. The scheme will facilitate pharmaceutical companies undertaking clinical trials on prospective Cannabis-based products and enable involvement in manufacture of product for supply to clinical trials and other patients with any pharmaceutical company free to bring forward a product for registration by the TGA based on clinical trials conducted overseas. The clinical trials being conducted by Australian states are seen to be necessary to increase the evidence base for Cannabis for medicinal purposes. There is sufficient evidence that Cannabis-based products may have a benefit to patients in certain clinical settings under appropriate medical supervision. The Government is concerned about the health and welfare of all Australians and wishes to ensure that they have access to the most appropriate and safe treatments available. Patients are expected to have access to medicinal Cannabis products manufactured from Cannabis legally cultivated in Australia as soon as the first half of 2017.